Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07541417 · ClinicalTrials.gov registry record · NA
Building Retention and Initiation Through Delivery of Peer-Guided Evidence-Based Practices
A NA study, sponsored by Prisma Health-Upstate.
- Recruiting
- Registry status
- NA
- Development phase
- 750
- Enrollment target
NCT07541417: Recruiting NA study, sponsored by Prisma Health-Upstate.
NCT07541417 is a NA study that is actively recruiting participants, run by Prisma Health-Upstate. The registered enrollment target is 750 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07541417, a NA study, is actively recruiting participants, sponsored by Prisma Health-Upstate.
- RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
Study Summary
This study will provide longitudinal data for 6-months on a target sample of patients with Opioid Use Disorder (OUD) recruited from Prisma Health Mobile Health Clinics in South Carolina. The goal of our study is to increase OUD treatment initiation and retention and maximize prevention of overdose deaths in underserved communities through development, testing, and delivery of a novel intervention targeting areas of optimal allocation of MHC with a Peer Support Specialist (PSS) intervention.
Primary Outcome
MOUD initiation defined as receipt of first MOUD prescription within 3 months since baseline assessment.
Interventions
- BEHAVIORAL Certified Peer Support Specialist Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2029-08-31 |
| Phase | NA |
What NCT07541417 shows while recruiting
NCT07541417 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Certified Peer Support Specialist Intervention is the first listed.
NCT07541417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07541417 about?
NCT07541417 is a clinical study titled "Building Retention and Initiation Through Delivery of Peer-Guided Evidence-Based Practices". This study will provide longitudinal data for 6-months on a target sample of patients with Opioid Use Disorder (OUD) recruited from Prisma Health Mobile Health Clinics in South Carolina. The goal of our study is to increase OUD treatment initiation and retention and maximize prevention of overdose d...
What is the current status of trial NCT07541417?
This trial is currently recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2026-04-08. Estimated completion is 2029-08-31.
What interventions are being tested in trial NCT07541417?
The interventions under investigation include: Certified Peer Support Specialist Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT07541417?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07541417's enrollment target sits among peer trials
750 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI